The Latest Breaking News from ABBV

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab.  Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy.  The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.4%. Currently, AbbVie has a market capitalization of $263.04 billion.

Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL). The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR…

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion.

Worries about looming recession due to the Fed's tighter monetary policy and other macroeconomic headwinds have kept the stock market under pressure. Amid such a scenario, investing in shares of stalwart companies Intel (INTC), AbbVie (ABBV), FedEx(FDX)), Oracle (ORCL), and The Coca-Cola (KO) could help investors dodge the short-term market…

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy.  AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and inflammatory diseases. Cugene's lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells for autoimmune…

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy.  A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and AbbVie Inc's (NYSE:ABBV) Allergan Plc are willing to pay more than $5 billion combined to resolve more than 3,500 lawsuits filed over highly addictive opioid painkillers, according to three people familiar with settlement talks.  The people said the companies have been in mediation talks with plaintiffs for more than a year. …